Operator
Good day, and thank you for standing by. Welcome to the Sangamo First Quarter 2021 Teleconference Call. [Operator Instructions].
I would now like to hand the conference over to your speaker today, Aron Feingold, Head of Corporate Communications. Please go ahead.
Aron Feingold
Head of Corporate Communications
Good afternoon, and thank you for joining us today. With me this afternoon on this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Mark McClung, Chief Business Officer; Jason Fontenot, Chief Scientific Officer; Rob Schott, Head of Development; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found on our website, sangamo.com, under the Investors and Media section on the Events and Presentations page.
Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys.
Here is what one of the more bearish critics had to say. The Rating
Goldman Sachs analyst Salveen Richter. Read More.
Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter s investigational gene therapy asset SRP-9001 outside of the U.S. The asset is being evaluated in. Read More.